Nath Bio-Genes (India) Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
NATHBIOGEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nath Bio-Genes has filed its annual disclosure under SEBI (SAST) Regulation 31(4) for the year ended March 31, 2025. The promoter group, including relatives and persons acting in concert, collectively holds 86,64,902 equity shares representing 45.60% of the company. During the financial year, the promoters created an encumbrance (pledge) on 14,19,000 equity shares, which had already been disclosed earlier. The filing is a routine annual compliance to confirm no undisclosed acquisition of shares was made by the promoter group during the year.
The disclosure confirms promoter holding remains below the 50% mark at 45.60%, keeping the company out of the mandatory open offer trigger zone. The pledged 14.19 lakh shares represent roughly 16% of promoter holdings, which is a moderate encumbrance level and something investors should monitor going forward.